MedTrace Logo

A Trial of SHR3162 in Healthy Caucasian Volunteers

NCT04333134 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2022-07-14

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and PK characteristics of a single oral dose of fluzoparib in healthy Caucasian and Chinese subjects

Conditions

  • Healthy Volunteers

Interventions

DRUG

SHR3162

Fluzoparib, also known as SHR3162, is an inhibitor of human PARP

Sponsors & Collaborators

  • Atridia Pty Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-04-17
Primary Completion
2020-05-15
Completion
2020-06-30

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04333134 on ClinicalTrials.gov